Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6746830 | 0.93 | ACHE (0.39) | DPP7MEN1KMT2ATDP1SCN8A | |
| SCHEMBL6744792 | 0.84 | TK1 (0.40) | DPP7 | |
| SCHEMBL6751558 | 0.83 | SIGMAR1 (0.36) | GAASIGMAR1 | |
| SCHEMBL6751602 | 0.79 | CA12 (0.43) | MEN1KMT2ACHRM2GAAMAPT | |
| SCHEMBL6751559 | 0.78 | MC4R (0.44) | MEN1KMT2ACHRM2SIGMAR1LMNA | |
| SCHEMBL6746847 | 0.77 | HTR2A (0.41) | TDP1 | |
| SCHEMBL8342160 | 0.76 | ALDH1A1 (0.42) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL7227853 | 0.74 | SCN8A (0.35) | MEN1KMT2ASCN8AMAOAACHE | |
| SCHEMBL6746868 | 0.74 | DRD2 (0.39) | MEN1KMT2ACHRM2 | |
| SCHEMBL7222807 | 0.73 | SCN8A (0.36) | MEN1KMT2ASCN8AACHEGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6703388-B2 | DIBENZODIAZEPINE DERIVATIVES; ANTIHISTAMINES, LEUKOTRIENE INHIBITORS, ANTIALLERGENS, ANTIASTHMATICS; HAY FEVER, ATOPIC DERMATITIS, AND URTICARIA TREATMENT | EISAI CO., LTD. (JP) | 2004-03-09 | — | — | US | disclosed |
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| US-6489336-B2 | PHENOTHIAZINE, ACRIDAN, ACRIDONE OXIME, ACRIDONE HYDRAZONE, OR DIBENZODIAZEPINE DERIVATIVES; TYROSINE KINASE INHIBITORS; TREATING ALLERGIC DISEASES | EISAI CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | EISAI CO., LTD. | 2002-08-01 | — | — | US | disclosed |
| US-6333322-B1 | FOR THERAPY OF ASTHMA, ALLERGIC RHINITIS, ATOPIC DERMATITIS, URTICARIA, HAY FEVER, GASTROINTESTINAL ALLERGY AND FOOD ALLERGY | EISAI CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-0889037-A1 | NITROGENOUS TRICYCLIC COMPOUNDS AND DRUGS COMPRISING THE SAME | Eisai Co., Ltd. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171367-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | DPP7 1956/4885MEN1 2589/4885KMT2A 2438/4885 |
| US-20020103189-A1 | Nitrogen-containing tricyclic compounds and drugs containing the same | HRH2, HRH1, HRH4 | DPP7 1956/4885MEN1 2589/4885KMT2A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.